Sensenig Bethany, a director at Supernus Pharmaceuticals ($SUPN), sold shares on the open market three times in the last year, totaling about $455 thousand. Her most recent sale occurred on February 19, 2026. These sales rank 6,666th among nearly 12,000 individual insiders, where the average is $8.6 million across 6.4 transactions. She made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 19, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | M | Restricted Stock Unit | 4475 | $0.00 | 0.0000 | 56,552,741 | 100.00% | 0.01% |
| Feb. 19, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | S | Common Stock | 3258 | $51.27 | 0.0000 | 56,552,741 | 100.00% | 0.01% |
| Feb. 19, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | S | Common Stock | 1217 | $50.31 | 3,258.0000 | 56,552,741 | 27.20% | 0.00% |
| Feb. 19, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | M | Common Stock | 4475 | $0.00 | 4,475.0000 | 56,552,741 | 9999.99% | 0.01% |
| Feb. 18, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | A | Restricted Stock Unit | 2989 | $0.00 | 2,989.0000 | 56,552,741 | 9999.99% | 0.01% |
| Feb. 18, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | A | Director Stock Option (Right to Buy) | 4977 | $0.00 | 4,977.0000 | 56,552,741 | 9999.99% | 0.01% |
| Oct. 1, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Sensenig Bethany | Not found | A | Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 53,883,681 | 9999.99% | 0.08% |
| Aug. 14, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | S | Common Stock | 5369 | $42.25 | 0.0000 | 55,958,537 | 100.00% | 0.01% |
| Feb. 22, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | A | Common Stock | 5369 | $0.00 | 5,369.0000 | 55,958,537 | 9999.99% | 0.01% |
| Feb. 22, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | D | Restricted Stock Units | 5369 | $0.00 | 0.0000 | 55,958,537 | 100.00% | 0.01% |
| Feb. 19, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | A | Restricted Stock Unit | 4475 | $0.00 | 4,475.0000 | 55,958,537 | 9999.99% | 0.01% |
| Feb. 19, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | A | Director Stock Option (Right to Buy) | 7296 | $0.00 | 7,296.0000 | 55,958,537 | 9999.99% | 0.01% |
| Feb. 22, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | A | Director Stock Option (Right to Buy) | 8252 | $0.00 | 8,252.0000 | 55,506,828 | 9999.99% | 0.01% |
| Feb. 22, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | A | Restricted Stock Units | 5369 | $0.00 | 5,369.0000 | 55,506,828 | 9999.99% | 0.01% |
| Aug. 17, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | Sensenig Bethany | Director | A | Director Stock Option (Right to Buy) | 24153 | $0.00 | 24,153.0000 | 61,679,800 | 9999.99% | 0.04% |